ABSTRACT
BACKGROUND: Alopecia areata (AA) occurs with the apparition of asyntomatic non inflamatory alopecia plaques without scars. We distinguish several variants which are divided into two groups: typical forms (AA in single or multiple plaques) and atypical forms (by its presentation, evolution or paradoxical regrowth). OBJETIVES AND METHODS: We describe the cases of AA treated in our Trichology Unit between January 2000 and December 2011. RESULTS: We obtained 488 cases of AA. 114 (23.36%) were unusual form of AA or had paradoxical regrowth. The most common unusual form of AA was sisaipho type (7.37%), followed by AA for black and blonde hair (5.32%), atypical diffuse forms (4.30%), androgenetic alopecia type and (3.89%) and AA rectangular occipital (0.68%). Furthermore, we found nine cases of paradoxical regrowth (1.84%). CONCLUSIONS: Atypical variants of AA in our series are less than 25% of all cases, although it should be noted that since it is a specialized unit, we may be making a selection bias to be more difficult to diagnose cases or poor outcome.
Subject(s)
Alopecia Areata/classification , Adult , Alopecia Areata/diagnosis , Dermoscopy/methods , Diagnosis, Differential , Female , Follow-Up Studies , Hair/growth & development , Humans , Male , Prognosis , Retrospective Studies , Severity of Illness IndexSubject(s)
Cellulitis , Isotretinoin/therapeutic use , Scalp Dermatoses , Skin Diseases, Genetic , Adolescent , Adult , Biopsy , Cellulitis/diagnosis , Cellulitis/epidemiology , Cellulitis/therapy , Dermatologic Agents/therapeutic use , Female , Global Health , Humans , Male , Middle Aged , Morbidity/trends , Multicenter Studies as Topic , Retrospective Studies , Scalp , Scalp Dermatoses/diagnosis , Scalp Dermatoses/epidemiology , Scalp Dermatoses/therapy , Skin Diseases, Genetic/diagnosis , Skin Diseases, Genetic/epidemiology , Skin Diseases, Genetic/therapy , Spain/epidemiology , Young AdultSubject(s)
Drug Eruptions/etiology , Methotrexate/adverse effects , Skin/pathology , Adult , Drug Eruptions/diagnosis , Humans , Immunosuppressive Agents/administration & dosage , Immunosuppressive Agents/adverse effects , Injections, Subcutaneous , Male , Methotrexate/administration & dosage , Psoriasis/drug therapy , Skin/drug effectsSubject(s)
5-alpha Reductase Inhibitors/adverse effects , Alopecia/drug therapy , Dutasteride/adverse effects , Erectile Dysfunction/chemically induced , Finasteride/adverse effects , 5-alpha Reductase Inhibitors/therapeutic use , Dutasteride/therapeutic use , Finasteride/therapeutic use , Humans , Insulin Resistance , Libido , Male , Osteoporosis/chemically induced , Prostatic Hyperplasia/drug therapy , Prostatic Neoplasms/prevention & controlABSTRACT
A Lipschütz ulcer or 'ulcus vulvae acutum' is an acute simple ulceration of the vulva or vagina of non-venereal origin which can be associated with lymphadenopathy. Three cases are described with accompanying clinical photographs. Two cases refer to adolescents, one an infant, all without any history of sexual contact. The cases serve to illustrate a little known but potentially important differential diagnosis of vulval ulceration.
Subject(s)
Skin Ulcer/pathology , Vulvar Diseases/pathology , Adolescent , Anti-Bacterial Agents/therapeutic use , Female , Fusidic Acid/therapeutic use , Humans , Infant , Skin Ulcer/drug therapy , Vaginal Creams, Foams, and Jellies , Vulvar Diseases/drug therapyABSTRACT
OBJECTIVES: The aim of this study was to test the efficacy of latanoprost in eyelash alopecia areata (AA). DESIGN: This study is a 2-year prospective, non-blinded, non-randomized, bilateral eyelash alopecia controlled study. SETTING: The setting of this study was Trichology Unit, Virgen Macarena University Hospital, Seville, Spain. PATIENTS: We conducted a survey of 54 subjects with AA universalis treated with the protocol of the Trichology Unit of our Department. Control group comprised 10 subjects who received injections of 0.5 mg/cm(2) of triamcinolone acetonide (TAC) in their eyebrows and 1 mg/cm(2) of TAC injections in affected scalp. The treatment group included 44 subjects who received the same treatment as the control group in scalp and eyebrows but they also applied a drop of latanoprost 0.005% (50 microg/mL) ophthalmic solution in their eyelid margins every night. Subjects were reviewed every 3 months for 2 years. RESULTS: Forty subjects finished the study and four subjects were lost to follow-up. In the treatment arm of this study, the course was well tolerated and uncomplicated. Both investigators and patients evaluated the regrowth. The results we obtained were: complete regrowth in 17.5%, moderate regrowth in 27.5%, slight regrowth in 30% and without response in 25%. Moderate and total regrowth constituted a cosmetically acceptable response. The therapy was continuous and the response remained without any side effects. No patients had cosmetically acceptable eyelash regrowth in the control group. CONCLUSIONS: Latanoprost may be an effective drug in the treatment of eyelash AA because it induces acceptable responses (total and moderate) in 45% of the patients. A formal, blinded prospective unilateral controlled study will permit further understanding about this promising therapeutic agent for eyelash AA.